>替诺福韦酯（TDF）在亚洲患者高基线HBV-DNA病毒载量（HBV DNA≥9 log10拷贝/毫升） - 见附表海报报告
> Tenofovir Disoproxil Fumarate (TDF) in Asian Patients With High Baseline HBV-DNA Viral Load (HBV DNA ≥9 log10 copies/mL) - see attached full poster report
>
>
>
> Reported by Jules Levin
>
> Asian Pacific Association for the Study of the Liver (APASL) Liver Week, June 6–10, 2013, Singapore
>
>
>
> Scott Fung1, Stuart C. Gordon2, Zachary Krastev3, Andrzej Horban4, Jörg Petersen5, Jan Sperl6, Leland J. Yee7, Phillip Dinh7, Eduardo B. Martins7, John F. Flaherty7, Kathryn M. Kitrinos7, Vinod K. Rustgi8, Maria Buti9, Patrick Marcellin10
>
> 1University of Toronto, Toronto, Ontario, Canada; 2Henry Ford Health System, Detroit, MI, USA; 3University Hospital, St Ivan Rilsky, Sofia, Bulgaria; 4Warsaw Medical University, Warsaw, Poland; 5Liver Unit Asklepios Klinik St Georg, Hamburg, Germany; 6Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 7Gilead Sciences, Inc., Foster City, CA, USA; 8Metropolitan Liver Diseases, Fairfax, VA, USA; 9Hospital General Universitari Vall d´Hebron, Barcelona, Catalonia, Spain; 10Hôpital Beaujon, University of Paris, Clichy, France
>
> CONCLUSIONS
>
> TDF therapy is efficacious in Asian patients with baseline HVL (HBV DNA ≥9 log10 copies/mL)
> – All patients achieved HBV DNA undetectability
> – Patients with HVL may take longer to reach undetectability
> Asian patients with HVL have similar favorable outcomes to those without HVL Mean HBV DNA declines in Asian patients were similar to those in non-Asian patients
>
>
>结论
>
> TDF治疗是有效的，在亚洲患者的基线HVL（HBV DNA≥9 log10拷贝/毫升）
> - 所有患者达到HBV DNA不可检测
> - HVL患者可能需要更长的时间才能达到不可检测
>亚洲患者HVL平均在亚洲患者的HBV DNA下降类似于那些在非亚洲患者也有类似的有利结果，那些没有HVL
>